Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Reproduction

• Publication date

  2016-01-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1530/REP-15-0340PMID 26733727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adrenal androgen excess and body mass index in polycystic ovary syndrome.

  2015cited by this paper
• Adrenal androgen excess and body mass index in polycystic ovary syndrome.

  2015cited by this paper
• Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome.

  2014cited by this paper
• Impaired uterine artery flow associated with the presence of ovarian endometrioma: preliminary results of a prospective study

  2014cited by this paper
• Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias

  2014cited by this paper
• Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome

  2014influential reference
• Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with HIV-1 infection and syphilis or neurosyphilis.

  2011cited by this paper
• 早産児慢性肺疾患における neutrophil gelatinase-associated lipocalin (NGAL) の検討

  2011cited by this paper
• Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome

  2011influential reference
• Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome

  2011cited by this paper
• Tissue inhibitors of metalloproteinases

  2011influential reference
• Matrix metalloproteinases.

  2010cited by this paper
• The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study

  2010influential reference
• Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation.

  2010cited by this paper
• Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome.

  2010influential reference
• Matrix metalloproteinases involvement in pathologic conditions.

  2010cited by this paper
• Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene.

  2010cited by this paper
• Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models.

  2010influential reference
• [Structure and function of matrix metalloproteinases].

  2009cited by this paper
• Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.

  2009cited by this paper
• Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions

  2009cited by this paper
• which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Placental thrombomodulin expression in recurrent miscarriage

  2009cited by this paper
• Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies.

  2008influential reference
• Implications of polycystic ovary syndrome on oocyte development.

  2008cited by this paper
• Polycystic Ovary Syndrome and Oocyte Developmental Competence

  2008cited by this paper
• Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1

  2008influential reference
• Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review

  2008cited by this paper
• Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?

  2008influential reference
• Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

  2007cited by this paper
• Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.

  2007influential reference
• Elevated serum levels of matrix metalloproteinase‐2 in women with polycystic ovarian syndrome

  2007influential reference
• Structure and function of matrix metalloproteinases and TIMPs.

  2006cited by this paper
• Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome.

  2006cited by this paper
• Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.

  2005cited by this paper
• Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.

  2005cited by this paper
• MMPS and TIMPS in ovarian physiology and pathophysiology.

  2004influential reference
• Matrix Metalloproteinases 2 and 9 and Their Tissue Inhibitors in Low Malignant Potential Ovarian Tumors

  2004cited by this paper
• Men at risk: occupation and male infertility.

  2004cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

  2004cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  2004cited by this paper
• Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization.

  2003cited by this paper
• The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women.

  2001cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985influential reference
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls

  2025cites this paper
• Mechanistic Insights into PI3K/Akt-MMP9 Signaling in Crotonis Fructus-Induced Reproductive Toxicity via Integrated Network Toxicology and Multi-Model Validation.

  2025cites this paper
• MMP-9 dysregulation and chronic inflammation in polycystic ovary syndrome: linking ovulatory dysfunction to diagnostic implications

  2025cites this paper
• Toxicity and mechanism of bis(2-ethylhexyl) phthalate in premature ovarian failure: A network toxicology prediction and molecular docking analysis

  2025cites this paper
• Spotlight on Proteases: Roles in Ovarian Health and Disease

  2025cites this paper
• The Potential Role of Matrix Metalloproteinase in Polycystic Ovary Syndrome: Implications for Extracellular Matrix Remodeling

  2025cites this paper
• Proteomic analysis of human follicular fluid based on the 4D label free method to identify proteins that may affect oocyte quality in hyperandrogenic PCOS patients

  2025cites this paper
• Screening of Oxidative Stress-related Biomarkers and Antioxidant Drugs for Polycystic Ovary Syndrome Based on Bioinformatics and Molecular Docking

  2025cites this paper
• Exploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking

  2025cites this paper
• Overview of the expression patterns and roles of Lipocalin 2 in the reproductive system

  2024cites this paper
• Identification of key biomarkers for predicting atherosclerosis progression in polycystic ovary syndrome via bioinformatics analysis and machine learning

  2024cites this paper
• Association of uric acid and fructose levels in polycystic ovary syndrome.

  2024cites this paper
• Unraveling the pathogenic interplay between SARS-CoV-2 and polycystic ovary syndrome using bioinformatics and experimental validation

  2024cites this paper
• PLASMA PROLIDASE ACTIVITY AND ITS RELATION WITH NUMBER OF CYSTS IN POLYCYSTIC OVARY SYNDROME

  2024cites this paper
• DNA hypomethylation mediated transcription dysregulation participates in pathogenesis of polycystic ovary syndrome.

  2024cites this paper
• Evaluation of the Salivary Matrix Metalloproteinase-9 in Women With Polycystic Ovaries Syndrome and Gingival Inflammation: A Case-Control Study

  2023cites this paper
• Prediction of shared gene signatures and biological mechanisms between polycystic ovary syndrome and asthma: Based on weighted gene coexpression network analysis

  2023cites this paper
• The role of long non-coding RNA H19 in infertility

  2023cites this paper
• Insulin resistance is associated with increased circulating lipocalin-2 levels in polycystic ovary syndrome: a systematic review and meta-analysis.

  2023cites this paper
• Cardiovascular Health Does Not Change Following High-Intensity Interval Training in Women with Polycystic Ovary Syndrome

  2022cites this paper
• Two MMP2 gene polymorphisms significantly associated with polycystic ovary syndrome: A case-control analysis.

  2022cites this paper
• The expression and localization of selected matrix metalloproteinases (MMP-2, -7 and -9) and their tissue inhibitors (TIMP-2 and -3) in follicular cysts of sows.

  2022cites this paper
• Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome

  2022cites this paper
• Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites

  2022cites this paper
• Bisphenol analogs AF, S and F: effects on functional characteristics of porcine granulosa cells.

  2021cites this paper
• Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?

  2021cites this paper
• Identi � cation the key genes between polycystic ovary syndrome and Non-Alcoholic Fatty Liver Disease

  2021cites this paper
• Insights Into the Regulation of Gynecological Inflammation-Mediated Malignancy by Metalloproteinases

  2021cites this paper
• The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking

  2021cites this paper
• Bisphenol analogs AF and S: Effects on cell status and production of angiogenesis-related factors by COV434 human granulosa cell line.

  2021cites this paper
• Risk of de novo severe carpal tunnel syndrome after bilateral oophorectomy: a population-based cohort study

  2021cites this paper
• Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology

  2020cites this paper
• Assessment of gingival in ammation indexes and matrix metalloproteinase (MMP-9) in patients with polycystic ovarian syndrome compared to control group

  2020cites this paper
• The novel relationship between Polycystic Ovary Syndrome and Temporomandibular Joint Disorders.

  2020cites this paper
• Overexpression of reactive oxygen species modulator 1 is associated with advanced grades of bladder cancer

  2020cites this paper
• Meta-analysis of gene expression profiles of lean and obese PCOS to identify differentially regulated pathways and risk of comorbidities

  2020cites this paper
• Beneficial effects of genistein in suppression of proliferation, inhibition of metastasis, and induction of apoptosis in PC3 prostate cancer cells

  2020cites this paper
• Protective role of arnebin-1 in rats with nonalcoholic fatty liver disease

  2019cites this paper
• Cross-disorder analysis of endometriosis and its comorbid diseases reveals shared genes and molecular pathways and proposes putative biomarkers of endometriosis.

  2019cites this paper
• Role of matrix metalloproteinase‐9 gene polymorphisms in glaucoma: A hospital‐based study in Chinese patients

  2019cites this paper
• Reactive Oxygen Species Modulator 1 (ROMO1), a New Potential Target for Cancer Diagnosis and Treatment

  2019cites this paper
• Association between tissue inhibitor of metalloproteinase (TIMP) genetic polymorphisms and primary ovarian insufficiency (POI).

  2019cites this paper
• Role Of Insulin Like Growth Factor in Polycystic Ovary Syndrome

  2018cites this paper
• Slush nitrogen vitrification of human ovarian tissue does not alter gene expression and improves follicle health and progression in long-term in vitro culture.

  2018cites this paper
• Activity of Matrix Metalloproteinase 2 and 9 in Follicular Fluid and Seminal Plasma and Its Relation to Embryo Quality and Fertilization Rate

  2018cites this paper
• The Relationship between Matrix Metalloproteinase Gene Polymorphisms and Tumor Type, Tumor Size, and Metastasis in Women with Breast Cancer in Central Iran

  2018cites this paper
• Genistein Induces Apoptosis and Inhibits Proliferation of HT29 Colon Cancer Cells

  2016cites this paper